The combined market valuation of top seven companies declined by Rs 45,962.77 crore last week with IT majors -- Infosys and TCS -- taking the maximum hit.
The company will co-promote Suncros brand across prescription and consumer channels to drive growth Sun Pharma will focus on dermatology as the fourth engine of growth for its OTC business. As part of this growth strategy, th
Drug major Sun Pharmaceutical Industries has sold two of its US-based manufacturing facilities along with 15 products to Frontida BioPharm Inc for an undisclosed amount.
Headwinds plaguing the country's largest drug-maker Sun Pharmaceutical will continue for next two-three quarters owing to pricing pressures and regulatory issues dogging its Halol plant, says a report.
Sun Pharma also said that its board has decided to evaluate a proposal for buyback of equity shares and will hold a meeting on June 23 for the purpose.
Sun Pharmaceutical Industries shares plunged nearly 6 per cent in late morning trade on Tuesday after the pharma company posted a weaker-than expected annual sales outlook as it grappled with increased competition in the Unit
Country's largest drug maker Sun Pharmaceutical Industries today reported a consolidated net profit of Rs 1,713.69 crore for the fourth quarter ended March 31, 2016.
Driven by a sharp rally in the stock market last week, the combined market valuation of top- 10 most valued Indian companies soared by a whopping Rs 98,598 crore, with ITC emerging as the biggest mover.
Sun Pharma shares rallied after it said that the umbrella pact and transaction agreements signed with Daiichi Sankyo and its overseas subsidiaries have been terminated due to divestment of Ranbaxy by the Japanese firm.
The combined market valuation of nine of the top 10 most valued Indian companies diminished by Rs 47,932.59 crore last week, with IT major TCS taking the biggest hit.
ICGEB will provide the technical know-how and pre-clinical expertise and Sun Pharma to develop this drug with appropriate pre-clinical & clinical studies to register it in India and other global markets
The IL-23p19 Therapeutic Antibody meets primary endpoints in both placebo-controlled studies and secondary endpoint in active-comparator etanercept arm
